Surveys Present Similar Pictures of Plight of VCs
This article was originally published in Start Up
Executive Summary
The state of venture capital investing in medical devices and biopharmaceuticals can be examined from different angles and perspectives, but each presents the same troubling image: the two sectors are commanding less and less interest from VCs, according to surveys conducted by Start-Up magazine and the National Venture Capital Association.
You may also be interested in...
Cowen Doubles Down On Royalties
Cowen Healthcare Royalty Partners and its peers are flush with cash and feeling a little adventurous. It might be good news for biotechs and their investors.
START-UP's 2011 Life Science Venture Capital Survey: Device Investors Feel The Sting Of FDA, Economy And Reform
START-UP's first life science venture survey asked all VCs how they feel about the state of the industry. Medical device VCs' answers reveal feelings of being beaten down by the FDA and the recession, and general concerns about the sector's ability to generate returns. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."